SEC EDGARSEP 41 min read$CAI

Spetzler David Baxley sold $14.8M of CAI

Spetzler David Baxley (President) sold 597,212 shares of Caris Life Sciences, Inc. (CAI) at an average of $24.84 ($24.76–$25.32, $14.83M total) across 3 trades over 2026-09-03 to 2026-09-04.

Original reporting

SEC EDGAR · Spetzler David Baxley

Published Sep 4, 2026, 8:59 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Sep 4, 2026, 10:10 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$CAI

Bearish

medium confidence

Mentioned

$CAI

Relevance

7/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CAIBearishLow

Why it matters

The sale represents a direct reduction in insider ownership, which can be interpreted as a negative signal by the market.

Market read

Insider sell of $14.8M is material for CAI and may influence short‑term price action.

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 7/10Novelty 8/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAIBearishMedium confidence

Context

President Spetzler David Baxley sold 597,212 shares of Caris Life Sciences for $14.8M, reducing his stake to 1.18M shares.

Expected impact

Modest downside pressure in the near term.

Evidence & confidence

A $14.8M sale by a top executive is material; markets often react negatively to insider disposals of this size.

Market effects

Sector

May raise concerns about biotech sector insider sentiment.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

Company
Caris Life Sciences, Inc.
Biotech firm developing AI-driven cancer diagnostics.
Executive
Spetzler David Baxley
President of Caris Life Sciences.

Read at source ← All news

AUG 27

$CAIMedAI 8/10

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Caris Life Sciences (NASDAQ: CAI) published a study in npj Precision Oncology on an AI tool for pancreatic cancer treatment. The tool, part of the Caris Molecular Tumor Board Report, predicts patient outcomes for two treatments, with median survival of 16 months for FOLFIRINOX vs. 9.9 months for gemcitabine plus nab-paclitaxel. The company's MI Cancer Seek test, FDA-approved in November 2024, includes this tool.

proactiveinvestors.com2 min

AUG 8

$CAIHighAI 9/10

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences (Nasdaq: CAI) reported Q2 2026 revenue of $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services to $252.3 million. It completed about 59,200 clinical cases and posted 68% gross margin. 2026 revenue guidance was raised to $1.03 to $1.04 billion.

aol.com5 min

AUG 7

$CAIMed

What’s Next For Caris Life Sciences Inc. (NASDAQ:CAI) After 21% Jump?

Caris Life Sciences (NASDAQ:CAI) shares rose up to about 21.6% after its Q2 results. The company cut net loss to $637,000 and increased revenue 45% to $263.7 million, driven by a 55% jump in molecular profiling services. It guided 2026 revenue of $1.03B to $1.04B and noted 59,200 clinical cases. Hedge fund holdings fell in Q1.

insidermonkey.com6 min

AUG 7

$CAIMed

What’s Next For Caris Life Sciences (CAI) After 21% Jump?

Caris Life Sciences (NASDAQ:CAI) shares rose up to 21.58% after Q2 results. The company cut net loss attributable to shareholders to $637,000 from $517.2M, while revenue rose 45% to $263.7M. Molecular profiling services revenue increased 55% to drive growth. Caris forecasts 2026 revenue of $1.03B-$1.04B and 26.8%-28% growth, and reaffirmed therapy selection volume growth guidance.

yahoo.com6 min

AUG 5

$CAIHigh

Caris Life Sciences, Inc. (CAI): Results of Operations and Financial Condition

Caris Life Sciences, Inc. (CAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole e

SEC EDGAR 8-K6 min

SEP 4

$MSCILow

Taneja Rajat purchased $1.0M of MSCI

Taneja Rajat purchased 1,786 shares of MSCI Inc. (MSCI) at $560.00 ($1.00M total) on 2026-09-02.

SEC EDGAR1 min